Patients with CFH or THBD/CD141 mutations had the earliest onset of aHUS and the highest mortality rates, whereas patients with MCP/CD46 mutations were associated with the least severe outcomes [16], but there was no significant relationship that could be identified between the type of mutation and the risk of HUS relapse in our study, which may be related to the differences in the background genetics of our population. Here, THBD is linked to hemolytic-uremic syndrome.